Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anthrax toxin: structures, functions and tumour targeting.

Shihui Liu1, Rebecca L Schubert, Thomas H Bugge

  • 1Microbial Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. shliu@niaid.nih.gov

Expert Opinion on Biological Therapy
|July 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Highly cited original research in microneedle science from 2015 to 2025 a bibliometric and altmetric analysis.

Discover nano·2026
Same author

SO<sub>2</sub>-Mediated Decarboxylative C(sp<sup>3</sup>)-C(sp<sup>3</sup>) Coupling of Carboxylic Acids Enabled by Photoredox Catalysis.

Chemistry, an Asian journal·2026
Same author

Genome sequence of protease-free <i>Bacillus</i> subtilis KO7-S strain created for protein production.

Microbiology resource announcements·2026
Same author

Genome sequence of protease-free <i>Bacillus anthracis</i> BH500 strain created for protein production.

Microbiology resource announcements·2026
Same author

Metabolic control of neuroinflammation: focus on itaconate and its derivatives in CNS disorders.

Frontiers in immunology·2026
Same author

A novel AAA+ ATPase required for sporulation and stress response in <i>Bacillus anthracis</i>.

Journal of bacteriology·2026
Same journal

Biologic modulation of ineffective erythropoiesis in thalassemia: mechanisms, clinical practice, and future targets.

Expert opinion on biological therapy·2026
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
See all related articles

Anthrax toxin

Area of Science:

  • Molecular Biology
  • Toxicology
  • Cancer Research

Background:

  • Bacillus anthracis secretes anthrax toxin, a key virulence factor comprising protective antigen (PrAg), lethal factor (LF), and edema factor (EF).
  • PrAg facilitates cellular entry of LF and EF, leading to cytotoxic effects via MAPKK inactivation.
  • Recent advancements in understanding anthrax toxin structure and function aid in developing antianthrax agents and exploring its therapeutic potential.

Purpose of the Study:

  • To investigate the potential of anthrax toxin, particularly lethal factor (LF), as a therapeutic agent for cancer treatment.
  • To explore modifications of protective antigen (PrAg) for targeted delivery and enhanced efficacy in cancer therapy.
  • To evaluate the antitumour effects of modified anthrax toxin on specific cancer types.

Main Methods:

Related Experiment Videos

  • Characterization of anthrax toxin structure and function.
  • Investigating the mechanism of lethal factor (LF) in inactivating mitogen-activated protein kinase kinases (MAPKKs).
  • Modifying the proteolytic activation site of protective antigen (PrAg) to alter its cleavage specificity.

Main Results:

  • Lethal factor (LF) effectively inactivates MAPKKs, demonstrating antitumour effects in certain cancers like human melanomas.
  • Altering the furin cleavage site of PrAg enables activation by tumour-specific proteases (e.g., MMPs, urokinase).
  • Modified anthrax toxin exhibits targeted cytotoxicity, limiting effects to specific cell types.

Conclusions:

  • Anthrax toxin, especially LF, holds promise for cancer therapy by targeting MAPK-dependent tumours.
  • Modifying PrAg's activation site offers a versatile strategy for targeted cancer treatment.
  • Tumour-specific protease activation of modified anthrax toxin enhances therapeutic potential and reduces off-target effects.